<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Screening for testicular cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Screening for testicular cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Screening for testicular cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth W Lin, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joann G Elmore, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2303345"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Testicular cancer accounts for only about 0.5 percent of cancers in men overall but is the most common malignancy in males between the ages of 15 and 35 years. Most testicular cancers are germ cell tumors. The prognosis with treatment is generally excellent.</p><p>This topic will review issues related to screening for testicular cancer, including the lack of evidence and low likelihood that routine screening improves favorable outcomes for this disease.</p><p>The epidemiology, clinical manifestations, and treatment for testicular cancer are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p></p><p class="headingAnchor" id="H18074155"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Both the incidence and mortality rate of testicular cancer are low, with a lifetime risk of diagnosis of 0.4 percent and an age-adjusted yearly incidence of 6 cases per 100,000 [<a href="#rid1">1,2</a>]. Worldwide, there are approximately 72,000 new testicular cancer cases and 9000 deaths each year [<a href="#rid3">3</a>]. In the United States, there are an estimated 9190 new diagnoses and approximately 440 deaths each year [<a href="#rid1">1</a>]. The incidence of testicular cancer has been increasing over recent decades for unknown reasons [<a href="#rid1">1,2,4-6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer", section on 'Epidemiology'</a>.)</p><p>Testicular cancer is one of the most curable solid neoplasms, even when diagnosed at an advanced stage, with a low mortality rate of &lt;0.3 deaths per 100,000 per year [<a href="#rid7">7</a>]. Localized tumors have a five-year survival rate above 99 percent, and even tumors with the poorest prognosis have five-year survival exceeding 72 percent [<a href="#rid8">8</a>]. More than 95 percent of men diagnosed with testicular cancer from 2013 to 2019 in the United States were alive five years later, and there are more than 291,000 testicular cancer survivors in the United States [<a href="#rid1">1,2</a>].<em> </em>(See  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors"</a>.)</p><p class="headingAnchor" id="H2303352"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Certain risk factors are well recognized, and other factors are thought to potentially increase the risk for testicular cancer. These are presented here briefly and discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer", section on 'Risk factors'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Known risk factors</strong> – Factors known to increase the risk for testicular cancer include cryptorchidism (history of undescended testis), history of contralateral testicular cancer, family history of testicular cancer (which may also be related to environmental factors), testicular atrophy, and hypospadias. Testicular cancer occurs more frequently among White and American Indian/Alaska Native men than among men of other races.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible risk factors</strong> – Other factors not conclusively shown to increase the risk for testicular cancer include environmental exposures, infertility, HIV, and testicular microlithiasis (microcalcification).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Not a risk factor</strong> – Vasectomy has <strong>not</strong> been shown to be a risk factor for developing testicular cancer.</p><p></p><p class="headingAnchor" id="H2303366"><span class="h1">RATIONALE FOR NOT SCREENING ROUTINELY</span><span class="headingEndMark"> — </span>We suggest NOT screening asymptomatic male adolescents or adults who do not have known risk factors for testicular cancer on the basis of uncertain, but likely limited benefits of screening and some likelihood of harms [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H2615394845"><span class="h2">Limited benefits</span><span class="headingEndMark"> — </span>In general, for screening to be beneficial, detection of an asymptomatic cancer at a preclinical stage needs to increase the potential for cure, minimize harms including treatment-related morbidity, and be reasonably cost-effective. The low incidence and high cure rate of testicular cancer make it unlikely that screening for testicular cancer would appreciably decrease the cancer mortality rate.</p><p>As detailed elsewhere, testicular cancer occurs relatively infrequently (see <a class="local">'Epidemiology'</a> above). A primary care clinician doing routine examinations could expect to diagnose one patient with testicular cancer every 20 to 25 years [<a href="#rid11">11</a>].</p><p>Another factor in the decision whether to screen is the comparative morbidity and mortality between treatments initiated at early and later stages of disease. For testicular cancer, the cure rate is high even when diagnosed at an advanced stage of disease and two-thirds of tumors are Stage I at diagnosis, so the potential that screening would spare treatment-related morbidity or mortality associated with more advanced disease is low [<a href="#rid1">1,7,12</a>].</p><p>Furthermore, to screen effectively, there must be useful methods, and for testicular cancer, there are no screening tests proven to be useful, as discussed below.</p><p class="headingAnchor" id="H944569883"><span class="h2">Limitations and potential harms of testicular examination</span><span class="headingEndMark"> — </span>Periodic palpation of the testes by the patient (self-examination) or clinician could lead to detection of testicular cancers before they cause noticeable symptoms. However, there are no studies of the sensitivity or specificity of clinician or self-examination for testicular cancer [<a href="#rid10">10</a>], so the utility of testicular examination for screening is unknown.</p><p>Harms of screening for testicular cancer with clinician or self-examination are likely minimal but could include false-positive results, anxiety, over-diagnosis, and adverse effects of subsequent diagnostic tests or procedures [<a href="#rid13">13</a>]. Opportunity costs (time and effort required<em> </em>by patients and the health system) of screening are also a consideration. A microsimulation model based on Dutch testicular cancer statistics projected that in a best-case scenario, annual self-examination from age 20 to 30 years would prevent fewer than five deaths from testicular cancer at the cost of 14,000 additional primary care and 2080 additional urology visits [<a href="#rid14">14</a>]. Systematic reviews have found no studies evaluating harms of screening with testicular examination [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H167459261"><span class="h2">No role for screening with biomarkers</span><span class="headingEndMark"> — </span>There are no blood tests considered to be useful for screening asymptomatic men for testicular cancer. (See  <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors", section on 'Clinical applications'</a>.)</p><p>Serum tumor markers include alpha fetoprotein (AFP) and the beta subunit of human chorionic gonadotropin (beta-hCG), one or both of which are elevated in approximately 90 percent of men with nonseminomatous testicular cancer, and lactate dehydrogenase (LDH) [<a href="#rid2">2</a>]. However, despite being useful in diagnosis, treatment, and surveillance of testicular cancer, these markers have insufficient sensitivity or specificity for screening [<a href="#rid2">2,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Serum tumor markers'</a>.)</p><p class="headingAnchor" id="H4261077191"><span class="h1">SELECT INDICATIONS FOR TESTICULAR EXAMINATION</span><span class="headingEndMark"> — </span>In selected clinical situations, including men with symptoms or signs suggestive of testicular cancer and men in a surveillance program subsequent to cancer treatment, clinician examination or patient self-examination may be warranted. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Testicular examination'</a>.)</p><p class="headingAnchor" id="H1740742521"><span class="h2">Symptomatic men</span><span class="headingEndMark"> — </span>Clinicians and patients should be aware of common presenting symptoms of testicular cancer so that any suggestive symptoms can be evaluated. </p><p>Common presentations of localized testicular cancer include a mass (with or without pain) in the testicle or scrotum (with or without tenderness), testicular firmness, and scrotal heaviness. Metastatic disease may cause symptoms including gynecomastia, abdominal or neck mass, or gastrointestinal or respiratory complaints [<a href="#rid16">16</a>]. Detection of testicular cancer provides an opportunity for the patient to receive treatment that has a very high likelihood of being effective. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H2344815427"><span class="h2">Surveillance after germ cell tumors</span><span class="headingEndMark"> — </span>Testicular examination should be performed at each visit following treatment of germ cell tumors because of the higher incidence of contralateral testis cancer in men with unilateral germ cell tumors and of testis cancers in men with primary extragonadal germ cell tumors. Clinical follow-up for men treated for testicular cancer is described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors"</a>.)</p><p class="headingAnchor" id="H3097584607"><span class="h2">History of cryptorchidism</span><span class="headingEndMark"> — </span>Men with a history of cryptorchidism have a higher risk of testicular cancer than the general population, with the highest risk being among those who underwent orchiopexy after puberty or who have not had orchiopexy. Monthly testicular self-examination may be warranted for these men [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management", section on 'Testicular cancer'</a>.)</p><p>The risk of testicular cancer in patients who have undergone orchiopexy prior to puberty may be incompletely defined because of the lack of longer-term data; the practice has only been recommended for the past two decades. However, for men who had surgical correction of cryptorchidism prior to puberty, we do not suggest monthly self-examination, because the benefits and harms have not been well studied. Some other experts, including other UpToDate contributors, do suggest monthly self-examination [<a href="#rid19">19</a>]. (See <a class="local">'Recommendations of others'</a> below and  <a class="medical medical_review" href="/z/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management", section on 'Long-term follow-up'</a>.)</p><p class="headingAnchor" id="H2303373"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Based on the low incidence of testicular cancer, the highly favorable treatment outcomes even in advanced disease, and potential harms associated with screening, many organizations recommend not screening asymptomatic males for testicular cancer; some organizations recommend that men with certain risk factors be screened with self-examination.</p><p class="bulletIndent1"><span class="glyph">●</span>The US Preventive Services Task Force (USPSTF) does not recommend screening for testicular cancer in asymptomatic adolescent or adult males [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Academy of Family Physicians recommends against screening for testicular cancer in asymptomatic males [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Academy of Pediatrics does not recommend screening for testicular cancer in asymptomatic males [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Cancer Society (ACS) does not have a recommendation on regular self-examination by all men because there are no studies showing these examinations reduce the death rate from testicular cancer. However, the ACS recommends that men with certain risk factors (eg, cryptorchidism, previous testicular cancer, or family history of testicular cancer) consider monthly self-examination [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The European Association of Urology recommends that males do testicular self-examination if they have clinical risk factors (eg, family history of testicular cancer) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Urologic Association advises that patients who were previously cryptorchid should perform monthly testicular self-examination after puberty to potentially help find cancer early [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H2068834553"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122274.html" rel="external">"Society guideline links: Testicular cancer"</a>.)</p><p class="headingAnchor" id="H184334525"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17164.html" rel="external">"Patient education: Varicocele (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2303380"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and prognosis</strong> –<strong> </strong>The incidence of testicular cancer is low and, although increasing over recent decades, accounts for only about 1 percent of cancers in men. Testicular germ cell tumors are one of the most curable solid neoplasms, with an overall cure rate greater than 90 percent. Even advanced tumors with the poorest prognosis have a five-year survival rate exceeding 72 percent. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for not screening routinely</strong> –<strong> </strong>We suggest <strong>not</strong> routinely screening asymptomatic males (adolescents or adults) for testicular cancer with either self-examination or periodic clinical examination (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The low incidence and high cure rate of testicular cancer make it unlikely that screening for testicular cancer would appreciably decrease the cancer mortality rate. (See <a class="local">'Rationale for not screening routinely'</a> above.)</p><p></p><p class="bulletIndent1">Although periodic palpation of the testes may detect a testicular cancer before noticeable symptoms occur, there are no studies of the sensitivity or specificity of either the clinical or self-examination for testicular cancer, and no evidence has shown that routine screening for testicular cancer through periodic clinical examinations or self-examinations would improve health outcomes. (See <a class="local">'Rationale for not screening routinely'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Select indications for testicular examination</strong> –<strong> </strong>Patients with a history of contralateral testicular cancer should do patient self-examination monthly and have clinician examination at periodic health-maintenance visits. It is reasonable also to advise men who have a history of cryptorchidism that is either uncorrected or was surgically corrected after puberty to perform monthly testicular self-examination. Some also advise this for men who had surgical correction prior to puberty. (See <a class="local">'Select indications for testicular examination'</a> above and <a class="local">'History of cryptorchidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> –<strong> </strong>Clinicians and patients should be aware of common presenting symptoms of testicular cancer so they can be evaluated. (See <a class="local">'Symptomatic men'</a> above and  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Testicular examination'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Surveillance, epidemiology, and end results program. Cancer stat facts: Testicular cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/testis.html (Accessed on November 03, 2023).</li><li><a class="nounderline abstract_t">Stevenson SM, Lowrance WT. Epidemiology and Diagnosis of Testis Cancer. Urol Clin North Am 2015; 42:269.</a></li><li><a class="nounderline abstract_t">Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3:524.</a></li><li><a class="nounderline abstract_t">McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97:63.</a></li><li><a class="nounderline abstract_t">Townsend JS, Richardson LC, German RR. Incidence of testicular cancer in the United States, 1999-2004. Am J Mens Health 2010; 4:353.</a></li><li><a class="nounderline abstract_t">Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170:5.</a></li><li class="breakAll">National Cancer Institute. Testicular cancer treatment (PDQ) summary: Health professional version. National Cancer Institute, Bethesda, MD, 2019. https://www.cancer.gov/types/testicular/hp/testicular-treatment-pdq (Accessed on December 05, 2019).</li><li><a class="nounderline abstract_t">van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006; 42:820.</a></li><li><a class="nounderline abstract_t">Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev 2011; :CD007853.</a></li><li><a class="nounderline abstract_t">Lin K, Sharangpani R. Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:396.</a></li><li class="breakAll">US Preventive Services Task Force. U.S. Preventive Services Task Force. In: Guide to Clinical Preventive Services, 2nd ed, US Department of Health and Human Services, Washington, DC 1996. p.153.</li><li class="breakAll">National Cancer Institute: PDQ® Testicular Cancer Screening. Bethesda, MD: National Cancer Institute. Date last modified 03/04/2016. Available at: . http://www.cancer.gov/types/testicular/hp/testicular-screening-pdq (Accessed on April 06, 2016).</li><li><a class="nounderline abstract_t">U.S. Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2011; 154:483.</a></li><li><a class="nounderline abstract_t">Heijnsdijk EAM, Supit SJ, Looijenga LHJ, de Koning HJ. Screening for cancers with a good prognosis: The case of testicular germ cell cancer. Cancer Med 2021; 10:2897.</a></li><li><a class="nounderline abstract_t">Mir MC, Pavan N, Gonzalgo ML. Current Clinical Applications of Testicular Cancer Biomarkers. Urol Clin North Am 2016; 43:119.</a></li><li><a class="nounderline abstract_t">Shaw J. Diagnosis and treatment of testicular cancer. Am Fam Physician 2008; 77:469.</a></li><li><a class="nounderline abstract_t">Lip SZ, Murchison LE, Cullis PS, et al. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child 2013; 98:20.</a></li><li><a class="nounderline abstract_t">Chan E, Wayne C, Nasr A, FRCSC for Canadian Association of Pediatric Surgeon Evidence-Based Resource. Ideal timing of orchiopexy: a systematic review. Pediatr Surg Int 2014; 30:87.</a></li><li><a class="nounderline abstract_t">Kolon TF, Herndon CD, Baker LA, et al. Evaluation and treatment of cryptorchidism: AUA guideline. J Urol 2014; 192:337.</a></li><li class="breakAll">American Academy of Family Physicians. Screening for testicular cancer. Available at: https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/cw-testicular-cancer.html (Accessed on October 04, 2021).</li><li class="breakAll">American Academy of Pediatricians. Recommendations for preventive pediatric health care. Available at: https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf (Accessed on November 16, 2022).</li><li class="breakAll">American Cancer Society: Can Testicular Cancer Be Found Early? https://www.cancer.org/cancer/testicular-cancer/detection-diagnosis-staging/detection.html (Accessed on June 13, 2017).</li><li class="breakAll">http://uroweb.org/guideline/testicular-cancer/ (Accessed on June 08, 2017).</li></ol></div><div id="topicVersionRevision">Topic 16286 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://seer.cancer.gov/statfacts/html/testis.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Surveillance, epidemiology, and end results program. Cancer stat facts: Testicular cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/testis.html (Accessed on November 03, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216814" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology and Diagnosis of Testis Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918777" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12491506" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in the incidence of testicular germ cell tumors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031937" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of testicular cancer in the United States, 1999-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796635" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Increasing incidence of testicular cancer worldwide: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796635" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increasing incidence of testicular cancer worldwide: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16574403" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328302" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Screening for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855803" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855803" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855803" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464350" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33710779" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Screening for cancers with a good prognosis: The case of testicular germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26614034" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Current Clinical Applications of Testicular Cancer Biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18326165" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnosis and treatment of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23193201" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24232174" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ideal timing of orchiopexy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24857650" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation and treatment of cryptorchidism: AUA guideline.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
